A pill could help prevent breast cancer in half a million women who are at high risk of getting the dreaded disease.
Doctors were given the go-ahead to prescribe the drug in a move hailed by experts as a "game changer".
Women with a family history of the illness will get the drug, costing less than 7 pence a day, after new guidance by the NHS medicines watchdog, the National Institute for Health and Care Excellence, the Daily Express reported.
Baroness Delyth Morgan, chief executive of Breast Cancer Campaign, said that this is a truly historic moment in the treatment of women at increased risk of breast cancer.
The drug, either in the form of tamoxifen or raloxifene, could help more than 488,000 women in England and Wales dramatically slash their risk of breast cancer.
It would be taken in much the same way that daily cholesterol-busting statins are taken by millions of people to stave off heart attacks and stroke.
Nice updated its guidelines on tamoxifen and raloxifene for particular groups of women and men after a string of scientific studies showed the drugs can stop people getting breast cancer if taken for five years.
The treatment will be offered to women aged 35 and over deemed to have a high risk (more than 30 percent) or moderate risk (17 to 30 percent) of contracting the illness.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
